Glaxosmithkline | GSK - Pre Utilidad Fiscal





Pre Utilidad Fiscal Cambio Fecha
AbbVie USD 7.87B 253M 2026-09
Amgen USD 4.19B 1.42B 2026-09
AstraZeneca USD 5.49B 684.4M 2026-09
Aurora Cannabis CAD -3.63M 15.04M 2026-06
Bausch Health Companies USD 597M 249M 2026-09
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Canopy Growth CAD -14.71M 143.26M 2026-06
Corcept Therapeutics USD 120.31M 74.38M 2026-09
Drreddys Laboratories INR 12.28B 10.28B 2026-09
Eli Lilly USD 8.79B 457M 2026-09
GlaxoSmithKline GBP 2.68B 532M 2026-06
Glaxosmithkline GBP 1.94B 209M 2026-09
J&J USD 7.67B 988M 2026-09
Merck USD -683M 2.85B 2026-06
Novartis USD 4.27B 430M 2026-06
Pacira USD 28.81M 26.26M 2026-09
Perrigo USD -18.1M 123.5M 2026-09
Pfizer USD 3.38B 4.04B 2026-09
Phibro Animal Health USD 38.62M 1.26M 2025-12
Prestige Brands USD 38.54M 26.23M 2026-06
Roche Holding CHF 11.17B 6.38B 2026-06
Sanofi EUR 5.28B 4.44B 2026-09
Supernus Pharmaceuticals USD 22.71M 80.36M 2026-09
Takeda JPY 155.97B 6.75B 2026-09
Teva Pharmaceutical Industries USD 300M 755M 2026-09
Zoetis USD 866M 108M 2026-06